Epoch Investment Partners Inc. Makes New Investment in Privia Health Group, Inc. $PRVA

Key Points

• Epoch Investment Partners Inc. acquired 41,062 shares of Privia Health Group, Inc. valued at approximately $922,000 in the first quarter, indicating growing institutional interest in the company.
• Analysts have mixed ratings for PRVA, with price objectives ranging from $24.00 to $35.00, reflecting a consensus target price of $28.00, signifying a "Moderate Buy" outlook.
• Privia Health Group reported revenue of $521.15 million in the last quarter, exceeding estimates, but missed earnings per share expectations by $0.03, earning only $0.02 per share.

Epoch Investment Partners Inc. acquired a new stake in Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 41,062 shares of the company's stock, valued at approximately $922,000.

A number of other institutional investors have also recently made changes to their positions in PRVA. Van Berkom & Associates Inc. acquired a new position in shares of Privia Health Group in the first quarter valued at approximately $45,207,000. Nuveen LLC acquired a new position in Privia Health Group during the 1st quarter worth approximately $26,899,000. Durable Capital Partners LP grew its holdings in Privia Health Group by 3.4% during the 4th quarter. Durable Capital Partners LP now owns 11,487,843 shares of the company's stock worth $224,587,000 after acquiring an additional 378,255 shares in the last quarter. Royce & Associates LP acquired a new position in Privia Health Group during the 1st quarter worth approximately $6,818,000. Finally, Nuveen Asset Management LLC grew its holdings in Privia Health Group by 19.8% during the 4th quarter. Nuveen Asset Management LLC now owns 1,488,979 shares of the company's stock worth $29,110,000 after acquiring an additional 246,393 shares in the last quarter. Institutional investors and hedge funds own 94.48% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have commented on PRVA. JPMorgan Chase & Co. boosted their price target on shares of Privia Health Group from $29.00 to $32.00 and gave the stock an "overweight" rating in a report on Wednesday, May 28th. Citigroup reiterated an "outperform" rating on shares of Privia Health Group in a research report on Friday. Zacks Research upgraded shares of Privia Health Group from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 19th. Evercore ISI cut their price objective on shares of Privia Health Group from $30.00 to $28.00 and set an "outperform" rating for the company in a research report on Wednesday, July 9th. Finally, Barclays upped their price objective on shares of Privia Health Group from $23.00 to $24.00 and gave the stock an "equal weight" rating in a research report on Tuesday, May 27th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $28.08.

Privia Health Group Stock Performance

NASDAQ PRVA traded up $1.23 during trading hours on Monday, reaching $23.04. The company's stock had a trading volume of 1,240,437 shares, compared to its average volume of 1,007,790. The stock has a market cap of $2.83 billion, a PE ratio of 209.47, a PEG ratio of 3.37 and a beta of 0.82. Privia Health Group, Inc. has a fifty-two week low of $16.47 and a fifty-two week high of $26.09. The company's 50-day moving average is $20.91 and its two-hundred day moving average is $22.63.

Privia Health Group (NASDAQ:PRVA - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.02 EPS for the quarter, missing analysts' consensus estimates of $0.05 by ($0.03). The business had revenue of $521.15 million during the quarter, compared to analyst estimates of $466.97 million. Privia Health Group had a net margin of 0.78% and a return on equity of 2.13%. Privia Health Group's revenue was up 23.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.19 earnings per share. Privia Health Group has set its FY 2025 guidance at EPS. Equities analysts expect that Privia Health Group, Inc. will post 0.14 earnings per share for the current fiscal year.

Privia Health Group Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.